Outcomes of down-titration in patients with severe scalp alopecia areata initially treated with baricitinib 4-mg: Week 152 data from BRAVE-AA2
Journal of the American Academy of Dermatology · 2025
DOI: 10.1016/j.jaad.2024.09.072 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of the American Academy of Dermatology, 2025. Verfasst von Brett King und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Yale School of Medicine, New Haven, Connecticut. Electronic address: brett.aking@gmail.com. Hauptthemen laut MEDLINE: Alopecia Areata, Azetidines, Sulfonamides, Janus Kinase Inhibitors. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 10 Literaturangaben. Gefördert von: Eli Lilly and Company.
Abstract (Originalsprache)
BACKGROUND: Baricitinib, an oral selective Janus kinase inhibitor, is approved to treat adults with severe alopecia areata (AA). OBJECTIVE: To report the week 152 efficacy results from the phase 3 trial BRAVE-AA2 down-titration substudy. METHODS: BRAVE-AA2 enrolled 546 adults with severe AA (Severity of Alopecia Tool [SALT] score ≥50). Baricitinib 4-mg-treated patients achieving a clinical response (SALT score ≤20) at week 52 were rerandomized 1:1 to stay on 4-mg or down-titrate to 2-mg. The last observation carried forward was used to impute missing or censored data. RESULTS: At week 52, 86/234 (36.8%) baricitinib 4-mg-treated patients were eligible for down-titration; 44 remained on 4-mg while 42 down-titrated to 2-mg. At week 152, 39/44 (88.6%) 4-mg-treated patients had maintained clinical response, compared to 24/41 (58.5%) down-titrated patients. Among down-titrated patients, loss of treatment benefit was less frequent in those with sustained response and SALT score ≤5 at week 52. LIMITATIONS: Method and timing of down-titration were prespecified in the protocol based on week 52 responder status and not on other clinical factors. CONCLUSION: More than half of down-titrated patients maintained response. Sustained treatment response and/or near-total regrowth may be associated with a greater likelihood of response maintenance after down-titration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Yale School of Medicine, New Haven, Connecticut. Electronic address: brett.aking@gmail.com.
- Department of Dermatology, Kyorin University Faculty of Medicine, Tokyo, Japan.
- Department of Dermatology, Lahey Hospital & Medical Center, and Harvard Medical School, Boston, Massachusetts.
- The Ronald O. Perelman Department of Dermatology, New York University Grossman School of Medicine, New York, New York.
- Eli Lilly and Company, Indianapolis, Indiana.
- Tigermed BDM Inc, Somerset, New Jersey.
Förderung
- Eli Lilly and Company
Zitieren
APA
King, B., Ohyama, M., Senna, M., Shapiro, J., Dutronc, Y., Durand, F., Liu, C., Yu, G., Kolodsick, J., Chiasserini, C., Somani, N., & Piraccini, B. M. (2025). Outcomes of down-titration in patients with severe scalp alopecia areata initially treated with baricitinib 4-mg: Week 152 data from BRAVE-AA2. Journal of the American Academy of Dermatology. https://doi.org/10.1016/j.jaad.2024.09.072
Vancouver
King B, Ohyama M, Senna M, Shapiro J, Dutronc Y, Durand F, et al. Outcomes of down-titration in patients with severe scalp alopecia areata initially treated with baricitinib 4-mg: Week 152 data from BRAVE-AA2. Journal of the American Academy of Dermatology. 2025. doi:10.1016/j.jaad.2024.09.072
BibTeX
@article{King2025,
author = {King, Brett and Ohyama, Manabu and Senna, Maryanne and Shapiro, Jerry and Dutronc, Yves and Durand, Frederick and Liu, Chunyuan and Yu, Guanglei and Kolodsick, Jill and Chiasserini, Chiara and Somani, Najwa and Piraccini, Bianca Maria},
title = {Outcomes of down-titration in patients with severe scalp alopecia areata initially treated with baricitinib 4-mg: Week 152 data from BRAVE-AA2},
journal = {Journal of the American Academy of Dermatology},
year = {2025},
doi = {10.1016/j.jaad.2024.09.072}
}
EUVIMED